Abstract
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5′ triphosphate-binding site. Somatic activating mutations of the EGFR gene, increased gene copy number and certain clinical and pathological features have been associated with dramatic tumor responses and favorable clinical outcomes with these agents in patients with non-small-cell lung cancer (NSCLC). The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene. Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed ‘classical’ mutations. The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes. Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease. The point mutation T790M accounts for about one half of these cases of acquired resistance. Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494–6501.
Bazley LA, Gullick WJ . (2005). The epidermal growth factor receptor family. Endocr Relat Cancer 12 (Suppl 1): S17–S27.
Bianco R, Gaofalo S, Rosa R, Damiano V, Gelardi T, Daniele G et al. (2008). Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98: 923–930.
Bonomi PD, Buckingham L, Coon J . (2007). Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13 (15 Suppl): 4606s–4612s.
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97: 643–655.
Carey KJ, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S et al. (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163–8171.
Ciardello F, Tortora G . (2008). EGFR antagonists in cancer treatment. N Engl J Med 358: 1160–1174.
Cortez-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A et al. (2005). Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081–1086.
Douillard JY, Hirsch V, Mok TS, Socinski MA, Watkins C, Lowe E et al. (2008). Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) (abstract). J Clin Oncol 26 (Suppl): abstract no. 8001.
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900–5909.
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T et al. (2008). PF00299804, an irreversible pan ErbB inhibitor, is effective in lung cancer models with EGFR and HER2 mutations that are resistant to gefitinib. Cancer Res 67: 11924–11932.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Duillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237–2246.
Gazdar AF, Minna JD . (2005). Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med 2: e377.
Gazdar AF, Minna JD . (2008). Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res 1: 156–160.
Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2: e313.
Han SE, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS et al. (2005). Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493–2501.
Hirsch FR, Franklin WA, McCoy J . (2006). Predicting clinical benefit from EGFR TKIs: not all EGFR mutations are equal (abstract). J Clin Oncol 24: 382s.
Ikeda K, Nomori H, Takeshi M, Sasaki K, Kobayashi T . (2008). Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 85: 1430–1432.
Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA et al. (2006). Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908–3914.
Jänne PA, Johnson BE . (2006). Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12 (14 Suppl): 4416s–4420s.
Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD . (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968–8974.
Kancha RK, von Bubnoff N, Peschel C, Duyster J . (2009). Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 15: 460–467.
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352: 786–792.
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T . (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919–8923.
Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764–5769.
Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290: 2149–2158.
Kumar A, Petri ET, Halmos B, Boggon TJ . (2008). Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742–1751.
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGFR receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702–4711.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
Maheswaran S, Sequist LV, Nagrath S, Ulkus L . (2008). Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med 359: 1–12.
Miller VA, Kris MG . (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103–1109.
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S et al. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513–2520.
Mok T, Wu Y-L, Thongprasert S, Yang C-H, Chu D, Saijo N et al. (2008). Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS) (abstract). Ann Oncol 19 (Suppl 8): LBA2.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005a). Acquired resistance of lung adenocarcinomas to gefitinib and erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. (2005b). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
Paz-Ares L, Sanchez JM, Garcia-Velasco B . (2006). A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) (abstract). J Clin Oncol 24 (Suppl): 369s.
Perez-Soler R, Chachoua A, Hammond LA, Rowinski EK, Huberman M, Karp D et al. (2004). Determinants of tumor response and survival and erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22: 3238–3247.
Politi K, Zakowski MF, Fan PD, Schoenfeld EA, Pao W, Varmus HE . (2006). Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancer respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496–1510.
Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839–844.
Sharma SV, Bell DW, Settleman J, Haber DA . (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.
Shepherd F, Tsao MS . (2006). Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24: 1219–1220.
Shepherd FA, Pereria J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. (2005). Erlotinib in previously treated non-small cell lung cancer. N Eng J Med 353: 123–132.
Shigematsu H, Gazdar AF . (2006). Somatic mutations of epidermal growth factor receptor-signaling pathway in lung cancers. Int J Cancer 118: 257–262.
Takano T, Ohe Y, Sakamotto H, Tsuta K, Matsuno Y, Tateishi U et al. (2005). Epidermal growth factor receptor gene mutations and increased copy number predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829–6837.
Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multi-centre study (Iressa survival evaluation in lung cancer). Lancet 366: 1527–1537.
Wong KK . (2007). HKI-272 in non-small cell lung cancer. Clin Cancer Res 13 (15 Part 2): S4593–S4596.
Yang C-H, Yu C-J, Shih J-Y, Cheng Y-C . (2008). Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib therapy. J Clin Oncol 26: 2745–2753.
Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK et al. (2008). The T790 mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070–2075.
Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM . (2009). Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076–2084.
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J . (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137–1149.
Acknowledgements
I thank Johnathan C Maher, PhD of BlueSpark Healthcare Communications for medical and editorial assistance with this article. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals Inc. Supported by grant P50CA70907 from the Specialized Programme for Research Excellence in Lung Cancer from the National Cancer Institute, Bethesda, MD, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gazdar, A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 (Suppl 1), S24–S31 (2009). https://doi.org/10.1038/onc.2009.198
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.198
Keywords
This article is cited by
-
A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition
npj Precision Oncology (2024)
-
In-silico identification and exploration of small molecule coumarin-1,2,3-triazole hybrids as potential EGFR inhibitors for targeting lung cancer
Molecular Diversity (2024)
-
Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action
Chinese Medicine (2023)
-
Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case–control study
Genes and Environment (2023)
-
EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis
Communications Biology (2023)